Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 2/2006

01-11-2006 | Oral Presentation

Benefits of combined treatments using antiresorptive agents and cytotoxic drugs

Authors: I Holen, H Neville-Webbe, RE Coleman

Published in: Breast Cancer Research | Special Issue 2/2006

Login to get access

Excerpt

Breast cancer patients often receive a combination of different therapies, but our understanding of how best to utilise such combinations to achieve maximal benefit for the patients is incomplete. We have investigated the ability of the antiresorptive agent zoledronic acid (Zol) and the commonly used chemotherapy agents paclitaxel (Pac) and doxorubicin (Dox) to induce apoptotic breast cancer cell death in vitro. …
Metadata
Title
Benefits of combined treatments using antiresorptive agents and cytotoxic drugs
Authors
I Holen
H Neville-Webbe
RE Coleman
Publication date
01-11-2006
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 2/2006
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1555

Other articles of this Special Issue 2/2006

Breast Cancer Research 2/2006 Go to the issue

Poster Presentation

Effect of intermittent versus chronic energy restriction on breast cancer risk biomarkers in premenopausal women: a randomised pilot trial

Poster Presentation

Development of small-molecule transforming growth factor beta antagonists

Oral Presentation

Genome-wide RNAi to identify genes that confer synthetic lethality with BRCA1

Oral Presentation

Microarray studies reveal novel genes associated with endocrine resistance in breast cancer

Poster Presentation

The Cambridge breast intensity modulated radiotherapy trial

Poster Presentation

Role of the Brk tyrosine kinase in breast cancer progression
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits